Alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) is a rare congenital condition characterised by abnormal development of the pulmonary vasculature. It manifests as severe, refractory hypoxaemia and persistent pulmonary hypertension of the newborn (PPHN), often resulting in rapid progression to respiratory failure and early death despite aggressive interventions. Diagnosis relies on distinct histological features. We present the case of a term neonate born to parents with a history of third-degree consanguinity. The mother, a primigravida, delivered a male neonate vaginally with meconium-stained amniotic fluid. Despite a normal antenatal course, the neonate developed severe respiratory distress shortly after birth, which progressed rapidly. The baby exhibited severe hypercarbia and progressive hypoxia, with clinical and echocardiographic parameters suggestive of PPHN. Aggressive treatment, including high-frequency oscillatory ventilation, surfactant administration, vasodilators and inotropes, did not improve the condition. Persistent severe respiratory acidosis and worsening hypoxia ensued, ultimately leading to death due to refractory respiratory failure. A lung biopsy performed after the neonate's death confirmed ACD/MVP as the cause. Initially suspected as PPHN secondary to meconium aspiration syndrome, poor response to treatment redirected focus to congenital lung disease. This case emphasises the importance of recognising ACD/MPV in neonates with severe respiratory distress and pulmonary hypertension unresponsive to standard treatments. Early lung biopsy, despite potential risks, can confirm the diagnosis, guide prognosis and avoid ineffective therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2024-264699DOI Listing

Publication Analysis

Top Keywords

pulmonary hypertension
12
severe respiratory
12
alveolar capillary
8
capillary dysplasia
8
respiratory failure
8
respiratory distress
8
lung biopsy
8
pulmonary
5
severe
5
respiratory
5

Similar Publications

Aims: Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new-onset atrial fibrillation in patients with heart failure using linked real-world UK data from primary and secondary care, along with findings from genome-wide association studies.

Methods And Results: Among 163 174 participants with a diagnosis of HF (January 1998 to May 2016) from Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES), 111 595 participants had no previous history of AF (mean age 76.

View Article and Find Full Text PDF

To investigate the correlation between different prenatal imaging techniques in congenital diaphragmatic hernia (CDH) and their prognostic value.209 fetuses with CDH were enrolled in this retrospective cohort study. The prenatal ultrasound-based and MRI-based (MRI: magnetic resonance imaging) observed-to-expected lung-to-head ratio (o/e-LHR) and MRI-based relative fetal lung volume (rFLV) were evaluated and compared.

View Article and Find Full Text PDF

Introduction: Opioid-induced constipation (OIC) is a common side effect of chronic opioid therapy that significantly impacts quality of life and healthcare costs. Naldemedine, a peripherally acting mu-opioid receptor antagonist, has shown efficacy in treating OIC. However, real-world evidence on naldemedine use in the United States is limited, particularly in older adults.

View Article and Find Full Text PDF

Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.

Epilepsia

March 2025

University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.

Objective: We analyzed the long-term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open-label extension (OLE) study after participating in randomized controlled trials (RCTs) or commencing FFA de novo as adults.

Methods: Patients with DS who participated in one of three RCTs or were 19 to 35 years of age and started FFA de novo were included. Key endpoints were: incidence of treatment-emergent adverse events (TEAEs) in the safety population, and median percentage change in monthly convulsive seizure frequency (MCSF) from the RCT baseline to end of study (EOS) in the modified intent-to-treat (mITT) population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!